About AXONIS Therapeutics
AXONIS Therapeutics is a company based in Cambridge (United States) founded in 2011 by Joanna Stanicka and Bob Yant. AXONIS Therapeutics has raised $124 million across 10 funding rounds from investors including R3, ARE and HHS. AXONIS Therapeutics offers products and services including AXN-027 and KCC2 Platform.
- Total Equity Funding$124M (USD)
in 10 rounds
- Latest Funding Round$115M (USD), Series A
Oct 2024
- InvestorsR3
& 21 more
Products & Services of AXONIS Therapeutics
AXONIS Therapeutics offers a comprehensive portfolio of products and services, including AXN-027 and KCC2 Platform.
AXN-027 is developed as a first-in-class oral KCC2 potentiator that is intended for treating epilepsy, pain, and other central nervous system disorders by restoring functional inhibition.
The KCC2 platform is utilized for advancing drug development in neurobiology, drawing on years of expertise to address neurological conditions.
Funding Insights of AXONIS Therapeutics
AXONIS Therapeutics has successfully raised a total of $124M across 10 strategic funding rounds. The most recent funding activity was a Series A round of $115 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $124M
- Total Rounds 10
- Last Round Series A — $115M
- Investors Count 22
All 10 funding rounds of AXONIS Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2024 | $115M | Series A | – | Cormorant Asset Management, VenBio | |
| Sep 2024 | $323,001 | Grant | – | – | |
| Jun 2023 | $299,756 | Grant | – | – | |
| Sep 2022 | $335,668 | Grant | – | – | |
| Sep 2022 | $298,819 | Grant | – | – | |
| Mar 2022 | $2.2M | Grant | – | – | |
| Jul 2021 | $5M | Seed | – | Alexandria | |
| Sep 2020 | $330,619 | Grant | – | – | |
| May 2020 | $4M | Seed | – | Alexandria | |
| Oct 2019 | – | Grant | – | – |
22 investors in total: 22 institutional.
Investors in AXONIS Therapeutics
AXONIS Therapeutics has secured backing from 22 investors, including institutional and venture fund investors. Prominent investors backing the company include R3, ARE and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Biotech funding, drug development support, and investment in life sciences. | – | sofinnova.com | - | |
Seed and early-stage therapeutics companies are invested in by MRLV. | – | mrlv.com | Cambridge, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Lumira Ventures is engaged in life sciences venture capital investment. | – | lumiraventures.com | Toronto, Canada | |
Venture capital firm focused on healthcare startups | – | solasta-ventures.com | Boston, United States | |
Eos BioInnovation is focused on incubating regenerative medicine companies. | – | eosbioinnovation.com | Cambridge, United States | |
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe | – | hatterasvp.com | Durham, United States | |
SCI Ventures is focused on funding innovative cures for paralysis. | – | sciventures.com | London, United Kingdom | |
- | – | tachyon.vc | - |
Investor details for AXONIS Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AXONIS Therapeutics
18 people are tracked at AXONIS Therapeutics (7 in leadership, 7 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Joanna Stanicka | Co-Founder & CEO | Leadership |
Bob Yant | Founder | Leadership |
Shane V. Hegarty | Chief Scientific Officer & Founder | Leadership |
Mike Wiecek | Senior Director, Finance & Operations | Leadership |
Patrick J. Carew, MBA, FACHE, CFRE | Founder, Board Member & Chief Operating Officer (coo) | Leadership |
Linda Jones | Consultant Director of Translation | Leadership |
Jennifer Burg | Senior Vice President, Clinical Development Operations | Leadership |
Corey S. Goodman | Director | Board & advisors |
Richard A. Sipos | Director | Board & advisors |
Lisa McKerracher | Scientific Advisor | Board & advisors |
James Guest | Scientific Advisor | Board & advisors |
Clifford Woolf | Scientific Advisor | Board & advisors |
Oswald Steward | Scientific Advisor | Board & advisors |
Yves De Koninck | Scientific Advisor | Board & advisors |
Adwitia Dey | Senior Scientist | Team |
Eilah Berlow | Business Operations Consultant | Team |
Grace Heely | Associate Scientist | Team |
Katerina Bubelo | Operations Associate | Team |
Complete people profiles for AXONIS Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AXONIS Therapeutics
3 dated milestones of AXONIS Therapeutics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded AXONIS Therapeutics is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $115.0M.
Web traffic of AXONIS Therapeutics
The website of AXONIS Therapeutics (axonis.us) receives about 4.9K visits a month.
- Monthly visits4.9K
▲ 23.9% vs previous month
Similar companies to AXONIS Therapeutics
10 companies that operate in the same segment as AXONIS Therapeutics (Clinical Trials & Research Tech), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Genetic services are provided by Colossal's laboratory operations. | 2021 | Austin, Texas, United States | USD 617.6 M | – | – | |
Research lab engaged in pharmacological measurements on therapeutic protein variants | 2018 | United States | USD 78.19 M | – | 22 | |
Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare. | 2004 | Ahmedabad, Gujarat, India | – | USD 50.52 M | 902 | |
Generic injectables for oncology and anesthesiology are manufactured. | 1989 | Hyderabad, Telangana, India | – | USD 4.22 M | 228 | |
Medical research labs are provided by GALY for scientific purposes. | 2018 | Boston, Massachusetts, United States | USD 61.59 M | – | 25 | |
Laboratory focused on biotechnology & molecule research services | 2018 | Cambridge, Massachusetts, United States | USD 32.68 M | – | – | |
Laboratory delivers discovery & research in nuclear and particle physics | 1947 | United States | – | – | 2,436 | |
Research and manufacturing of hemp products are conducted by BRC. | 2017 | Monterey, California, United States | USD 25.26 M | – | 16 | |
Genome sequencing studies are conducted for medical research purposes. | 2020 | Cambridge, Cambridgeshire, United Kingdom | USD 11.26 M | – | 12 | |
Novel immunotherapy therapeutic targets are discovered through laboratory research. | 2019 | Branford, Connecticut, United States | USD 92 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AXONIS Therapeutics
AXONIS Therapeutics was founded in 2011 and raised its 1st funding round 8 years after it was founded.
AXONIS Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Joanna Stanicka is the current CEO of AXONIS Therapeutics. They have also founded this company.
AXONIS Therapeutics is a funded company, having raised a total of $124M across 10 funding rounds to date.
AXONIS Therapeutics was established in 2011 and is headquartered in Cambridge, United States. Drug discovery services are delivered within the biotechnology sector, focusing on therapeutic development. Operations encompass target identification, lead optimization, and preclinical testing for pharmaceutical clients. The company operates through its domain axonis.us, with leadership held by Joanna Stanicka as Co-Founder and CEO, and Bob Yant as Founder. Geographic emphasis remains on the U.S. market.
AXONIS Therapeutics offers AXN-027 and KCC2 Platform.
AXONIS Therapeutics has 22 investors. Key investors include R3, ARE, HHS, Perceptive Advisors, and Christopher & Dana Reeve Foundation.
AXONIS Therapeutics operates through Axonis Therapeutics, Inc.